Rethinking Diabetes Care: PatentVest Pulse Unveils Key Insights on the Expanding CGM Market and the Innovations Driving Change
PatentVest has released a comprehensive report on the Continuous Glucose Monitoring (CGM) market, highlighting significant growth prospects and technological innovations in diabetes care. The report reveals that the global CGM market, valued at $11.63 billion in 2024, is projected to reach $21 billion by 2029.
The analysis addresses the critical need for continuous glucose monitoring solutions, noting that diabetes affects 537 million adults worldwide, with projections reaching 783 million by 2045. Key market drivers include technological advancements in non-invasive monitoring, integration with mobile applications, and the emergence of over-the-counter (OTC) CGM products.
The report emphasizes the competitive landscape dominated by major players like Dexcom, Abbott, Medtronic, and Roche, highlighting their role in transforming diabetes management through innovation and strategic market positioning. A surge in patent filings and ongoing litigation trends underscore the market's competitive nature.
PatentVest ha pubblicato un rapporto completo sul mercato del Monitoring Continuo della Glucosio (CGM), evidenziando le significative prospettive di crescita e le innovazioni tecnologiche nella cura del diabete. Il rapporto rivela che il mercato globale del CGM, valutato 11,63 miliardi di dollari nel 2024, è previsto raggiungere 21 miliardi di dollari entro il 2029.
L'analisi affronta la necessità critica di soluzioni per il monitoraggio continuo della glucosio, osservando che il diabete colpisce 537 milioni di adulti in tutto il mondo, con proiezioni che potrebbero raggiungere i 783 milioni entro il 2045. I principali fattori di crescita del mercato includono i progressi tecnologici nel monitoraggio non invasivo, l'integrazione con applicazioni mobili e l'emergere di prodotti CGM da banco (OTC).
Il rapporto sottolinea il panorama competitivo dominato da attori principali come Dexcom, Abbott, Medtronic e Roche, evidenziando il loro ruolo nel trasformare la gestione del diabete attraverso l'innovazione e il posizionamento strategico nel mercato. Un aumento dei depositi di brevetti e le tendenze in corso di contenzioso evidenziano la natura competitiva del mercato.
PatentVest ha lanzado un informe completo sobre el mercado del Monitoreo Continuo de Glucosa (CGM), destacando las importantes perspectivas de crecimiento e innovaciones tecnológicas en el cuidado de la diabetes. El informe revela que el mercado global de CGM, valorado en 11,63 mil millones de dólares en 2024, se proyecta que alcanzará 21 mil millones de dólares para 2029.
El análisis aborda la crítica necesidad de soluciones de monitoreo continuo de glucosa, señalando que la diabetes afecta a 537 millones de adultos en todo el mundo, con proyecciones que alcanzarán los 783 millones para 2045. Los principales impulsores del mercado incluyen avances tecnológicos en monitoreo no invasivo, integración con aplicaciones móviles y la aparición de productos CGM de venta libre (OTC).
El informe enfatiza el panorama competitivo dominado por los principales actores como Dexcom, Abbott, Medtronic y Roche, destacando su papel en la transformación de la gestión de la diabetes a través de la innovación y el posicionamiento estratégico en el mercado. Un aumento en las solicitudes de patentes y las tendencias de litigios en curso subrayan la naturaleza competitiva del mercado.
PatentVest는 지속적인 혈당 모니터링(CGM) 시장에 대한 포괄적인 보고서를 발표하며 당뇨병 관리에서 중요한 성장 가능성과 기술 혁신을 강조했습니다. 이 보고서는 2024년 116억 3천만 달러로 평가된 글로벌 CGM 시장이 2029년에는 210억 달러에 이를 것으로 예상된다고 밝혔습니다.
이 분석은 지속적인 혈당 모니터링 솔루션의 필요성을 강조하며, 전 세계적으로 당뇨병 환자가 5억 3700만 명에 달하고 있으며, 2045년까지 7억 8300만 명에 이를 것으로 전망하고 있습니다. 시장의 주요 동력은 비침습적 모니터링 기술의 발전, 모바일 애플리케이션과의 통합, 일반의약품(OTC) CGM 제품의 출현을 포함합니다.
보고서는 Dexcom, Abbott, Medtronic, Roche와 같은 주요 업체들이 혁신과 전략적 시장 포지셔닝을 통해 당뇨병 관리의 변화를 이끌고 있는 경쟁적인 시장 환경을 강조하고 있습니다. 특허 출원 급증과 현재 진행 중인 소송 경향은 시장의 경쟁적인 본질을 강조합니다.
PatentVest a publié un rapport complet sur le marché de la Surveillance Continue de la Glucose (CGM), mettant en évidence des perspectives de croissance significatives et des innovations technologiques dans le traitement du diabète. Le rapport révèle que le marché mondial du CGM, évalué à 11,63 milliards de dollars en 2024, devrait atteindre 21 milliards de dollars d'ici 2029.
Cette analyse aborde le besoin critique de solutions de surveillance continue de la glucose, notant que le diabète affecte 537 millions d'adultes dans le monde, avec des projections atteignant 783 millions d'ici 2045. Les principaux moteurs du marché incluent des avancées technologiques dans la surveillance non invasive, l'intégration avec des applications mobiles et l'émergence de produits CGM en vente libre (OTC).
Le rapport souligne le paysage concurrentiel dominé par des acteurs majeurs tels que Dexcom, Abbott, Medtronic et Roche, mettant en lumière leur rôle dans la transformation de la gestion du diabète grâce à l'innovation et au positionnement stratégique sur le marché. Une hausse des dépôts de brevets et des tendances de litige en cours soulignent la nature compétitive du marché.
PatentVest hat einen umfassenden Bericht über den Markt für Kontinuierliches Glukosemonitoring (CGM) veröffentlicht, der signifikante Wachstumsperspektiven und technologische Innovationen in der Diabetesversorgung hervorhebt. Der Bericht zeigt, dass der globale CGM-Markt, der 2024 auf 11,63 Milliarden Dollar geschätzt wird, bis 2029 auf 21 Milliarden Dollar anwachsen soll.
Die Analyse thematisiert den kritischen Bedarf an Lösungen für kontinuierliches Glukosemonitoring und weist darauf hin, dass weltweit 537 Millionen Erwachsene von Diabetes betroffen sind, mit Prognosen, die bis 2045 auf 783 Millionen ansteigen könnten. Zu den Haupttreibern des Marktes zählen technologische Fortschritte im nicht-invasiven Monitoring, die Integration mit mobilen Anwendungen und das Aufkommen von rezeptfreien (OTC) CGM-Produkten.
Der Bericht betont die Wettbewerbslandschaft, die von führenden Akteuren wie Dexcom, Abbott, Medtronic und Roche geprägt ist, und hebt deren Rolle bei der Transformation des Diabetesmanagements durch Innovation und strategische Marktpositionierung hervor. Ein Anstieg der Patentanmeldungen und anhaltende Rechtsstreittrends unterstreichen die Wettbewerbsnatur des Marktes.
- CGM market projected to grow from $11.63B (2024) to $21B (2029)
- Large addressable market with 537M diabetic adults worldwide, expected to reach 783M by 2045
- Expanding market opportunities through OTC products and non-invasive monitoring solutions
- None.
Insights
The CGM market is experiencing remarkable growth, with projections indicating a
The market dynamics reveal a strategic inflection point where traditional prescription-based models are evolving toward consumer-centric solutions. The addressable market is expanding beyond the current 537 million diabetic adults, potentially capturing a portion of the predicted 783 million patients by 2045. Simple terms: imagine a shift from specialized medical devices to consumer-friendly health tech, similar to how blood pressure monitors moved from clinics to homes.
Of particular interest is the competitive landscape transformation. Major players like Dexcom, Abbott, Medtronic and Roche are not just competing on technology but are racing to secure intellectual property rights. This patent activity suggests an imminent wave of product innovations and potential market consolidation. For investors, this signals both opportunities and risks in the CGM space, particularly for smaller players like MDBH who must navigate this increasingly competitive landscape.
The technological evolution in CGM systems represents a paradigm shift in diabetes management. The transition toward non-invasive monitoring solutions addresses a critical pain point in patient compliance and comfort. Think of it as moving from flip phones to smartphones - a fundamental improvement in user experience that drives adoption.
The integration of CGM devices with mobile applications and data analytics platforms is creating a connected ecosystem that enables predictive care and personalized treatment protocols. This connectivity enhances the value proposition beyond basic glucose monitoring to comprehensive diabetes management solutions.
For companies like MDBH, the OTC market opportunity is particularly significant as it lowers barriers to entry for new users and expands the potential customer base beyond insulin-dependent diabetics. However, success in this market will require balancing technological innovation with user-friendly design and competitive pricing strategies. The emphasis on patent protection suggests that novel technological approaches will be important for market differentiation.
Addison, TX, Jan. 07, 2025 (GLOBE NEWSWIRE) -- PatentVest, a leader in intellectual property (IP) intelligence and strategy, has released its latest report, “Continuous Glucose Monitoring (CGM): An Evolving Innovation Landscape.” This in-depth analysis explores the rapidly growing CGM market, offering valuable insights into the trends, key players, and opportunities that are shaping the future of diabetes care.
Diabetes is one of the most pressing global health challenges, affecting an estimated 537 million adults worldwide in 2021—a number projected to rise to 783 million by 2045. As the complexity of diabetes management grows, the need for continuous, real-time glucose monitoring has never been more critical. Continuous Glucose Monitors (CGMs) address these challenges by providing patients with timely insights into their glucose levels, enabling more informed decision-making and better health outcomes.
Valued at
Key Factors Shaping the Market:
- Technological Advancements: Innovations in CGM technology, including non-invasive glucose monitoring and seamless integration with mobile applications, are improving the convenience, accuracy, and accessibility of diabetes care.
- Market Dynamics: The emergence of OTC CGM products is broadening access to diabetes care, particularly for non-insulin-dependent patients and wellness-focused individuals, creating a significant shift in the market.
- Intellectual Property Strategy: The CGM market is characterized by a surge in patent filings, as companies race to protect their innovations and secure leadership positions. Ongoing litigation trends further highlight the high stakes in this rapidly evolving market.
“While there is currently no simple cure for diabetes, this report provides key insights into how major players like Dexcom, Abbott, Medtronic, and Roche are advancing innovative solutions to transform diabetes management,” said Will Rosellini, Chief IP Officer at PatentVest. “Through technological advancements, strategic market moves, and evolving IP strategies, these companies are shaping the future of diabetes care and expanding access to critical monitoring tools.”
PatentVest’s report provides in-depth analysis of these factors and offers actionable insights for companies, investors, and healthcare leaders navigating the CGM space.
Access the Full Report
The PatentVest Pulse report is now available. Gain comprehensive insights into the trends, technologies, and competitive dynamics driving the CGM market: Access the full report here.
For more information or inquiries, please contact info@patentvest.com.
About PatentVest
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm to enable visionary companies to develop into technology leaders. By combining our proprietary database with a time proven IP diligence process and expert analysis, we deliver actionable insights on the IP landscape to help our clients make informed decisions and stay ahead of the curve. The trends and competitive insights in this report are powered by PatentVest's proprietary IP intelligence platform. Our reports keep a pulse on the key players, technologies, and opportunities shaping deep technology markets.
FAQ
What is the projected market value for CGM technology by 2029?
How many people globally are affected by diabetes in 2021?
What are the key factors driving growth in the CGM market?
Who are the major players in the CGM market according to PatentVest?
What is the current market value of the CGM industry in 2024?
